Rafael Holdings, Inc. (RFL) - Form 8-K Summary
Business Context and Reporting Period
Company: Rafael Holdings, Inc.
Filing Date: April 22, 2026
Reporting Period: Current Report (Event Date: April 22, 2026)
Primary Business Event: The Company's subsidiary, Cyclo Therapeutics, LLC, entered into an exclusive licensing agreement with the Massachusetts Institute of Technology (MIT).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Strategic Development: The Company secured an exclusive license for U.S. Patent No. 12285440 from MIT.
Technology Scope: The patent covers the use of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation.
Outlook, Risks, and Management Commentary
- Forward-Looking Statements: The press release and this report contain forward-looking statements subject to risks and uncertainties.
- Regulatory Status: The information is furnished pursuant to Item 2.02 and is not deemed "filed" with the SEC unless expressly stated otherwise.
- Risks: Specific risks are referenced in the cautionary statements within the attached press release (Exhibit 99.1), but are not detailed in the body of this 8-K.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for details on the licensing agreement terms, including royalty rates or upfront payments.
- Verify the status of U.S. Patent No. 12285440 and the specific scope of the "exclusive" rights granted.
- Assess the clinical development stage of the cyclodextrin therapy for ApoE4-positive Alzheimer's patients.
- Monitor future filings for any financial impact resulting from this agreement.